Darwish_2024_Inflammopharmacology__

The aim of this study was to develop and evaluate bilosomes loaded with Celecoxib (CXB) for the efficient treatment of Alzheimer. The thin-film hydration approach was utilized in the formulation of CXB bilosomes (CXB-BLs). The study used a 2(3)-factorial design to investigate the impact of several formulation variables. Three separate parameters were investigated: bile salt type (X(1)), medication amount (X(2)), and lipid-bile salt ratio (X(3)). The dependent responses included entrapment efficiency (Y(1): EE %), particle size (Y(2): PS), and zeta potential ((Y3): ZP). The formulation factors were statistically optimized using the Design-Expert((a)) program. The vesicles demonstrated remarkable CXB encapsulation efficiency, ranging from 94.16 +/- 1.91 to 98.38 +/- 0.85%. The vesicle sizes ranged from 241.8 +/- 6.74 to 352 +/- 2.34 nm. The produced formulations have high negative zeta potential values, indicating strong stability. Transmission electron microscopy (TEM) revealed that the optimized vesicles had a spherical form. CXB release from BLs was biphasic, with the release pattern following Higuchi's model. In vivo studies confirmed the efficiency of CXB-BLs in management of lipopolysaccharide-induced Alzheimer as CXB-BLs ameliorated cognitive dysfunction, decreased acetylcholinesterase (AChE), and inhibited neuro-inflammation and neuro-degeneration through reducing Toll-like receptor (TLR4), and Interleukin-1beta (IL-1beta) levels. The findings suggested that the created CXB-BLs could be a potential drug delivery strategy for Alzheimer's treatment.